684 lines
31 KiB
HTML
684 lines
31 KiB
HTML
|
||
<!DOCTYPE html>
|
||
<html lang="zh-CN">
|
||
<head>
|
||
<meta charset="utf-8" />
|
||
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
|
||
<title>干细胞概念股分析报告</title>
|
||
<link href="https://fonts.googleapis.com/css?family=Inter:300,400,500,600,700,800" rel="stylesheet" />
|
||
<!-- Font Awesome Icons -->
|
||
<script src="https://kit.fontawesome.com/1d2b6c4f81.js" crossorigin="anonymous"></script>
|
||
<!-- Tailwind CSS -->
|
||
<link href="https://cdn.jsdelivr.net/npm/tailwindcss@2.2.19/dist/tailwind.min.css" rel="stylesheet">
|
||
<link href="https://cdn.jsdelivr.net/npm/daisyui@5" rel="stylesheet" type="text/css" />
|
||
<script src="https://cdn.jsdelivr.net/npm/@tailwindcss/browser@4"></script>
|
||
<style>
|
||
@import url('https://fonts.googleapis.com/css2?family=Noto+Sans+SC:wght@300;400;500;700&display=swap');
|
||
|
||
body {
|
||
font-family: 'Noto Sans SC', 'Inter', sans-serif;
|
||
background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
|
||
min-height: 100vh;
|
||
}
|
||
|
||
.glass-effect {
|
||
background: rgba(255, 255, 255, 0.85);
|
||
backdrop-filter: blur(10px);
|
||
border-radius: 16px;
|
||
box-shadow: 0 8px 32px 0 rgba(31, 38, 135, 0.15);
|
||
border: 1px solid rgba(255, 255, 255, 0.18);
|
||
}
|
||
|
||
.timeline-dot {
|
||
position: relative;
|
||
}
|
||
|
||
.timeline-dot::before {
|
||
content: '';
|
||
position: absolute;
|
||
width: 20px;
|
||
height: 20px;
|
||
border-radius: 50%;
|
||
background: #4f46e5;
|
||
left: -10px;
|
||
top: 5px;
|
||
z-index: 2;
|
||
}
|
||
|
||
.timeline-line {
|
||
position: absolute;
|
||
width: 2px;
|
||
background: #e5e7eb;
|
||
left: -1px;
|
||
top: 25px;
|
||
bottom: 0;
|
||
z-index: 1;
|
||
}
|
||
|
||
.highlight-box {
|
||
border-left: 4px solid #4f46e5;
|
||
padding-left: 16px;
|
||
margin: 16px 0;
|
||
}
|
||
|
||
.gradient-text {
|
||
background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
|
||
-webkit-background-clip: text;
|
||
-webkit-text-fill-color: transparent;
|
||
background-clip: text;
|
||
}
|
||
|
||
.particle-bg {
|
||
position: fixed;
|
||
top: 0;
|
||
left: 0;
|
||
width: 100%;
|
||
height: 100%;
|
||
z-index: -1;
|
||
opacity: 0.3;
|
||
}
|
||
|
||
.table-container {
|
||
overflow-x: auto;
|
||
}
|
||
|
||
@media (max-width: 768px) {
|
||
.timeline-dot::before {
|
||
width: 16px;
|
||
height: 16px;
|
||
left: -8px;
|
||
}
|
||
|
||
.timeline-line {
|
||
left: -1px;
|
||
}
|
||
}
|
||
</style>
|
||
</head>
|
||
<body class="p-4 md:p-8">
|
||
<div id="particles-js" class="particle-bg"></div>
|
||
|
||
<div class="max-w-7xl mx-auto">
|
||
<!-- 标题区域 -->
|
||
<div class="text-center mb-10">
|
||
<h1 class="text-4xl md:text-5xl font-bold gradient-text mb-4">干细胞概念股分析</h1>
|
||
<p class="text-gray-600 text-lg">从政策破冰到商业化元年的产业变革</p>
|
||
</div>
|
||
|
||
<!-- 核心观点摘要 -->
|
||
<div class="glass-effect p-6 mb-8">
|
||
<h2 class="text-2xl font-bold text-gray-800 mb-4 flex items-center">
|
||
<i class="fas fa-lightbulb text-yellow-500 mr-3"></i>
|
||
核心观点摘要
|
||
</h2>
|
||
<div class="grid grid-cols-1 md:grid-cols-3 gap-6">
|
||
<div class="bg-blue-50 rounded-lg p-4">
|
||
<h3 class="font-semibold text-blue-800 mb-2">阶段判断</h3>
|
||
<p class="text-gray-700">干细胞治疗已从政策驱动进入商业化验证期，2026年起大适应症数据将决定行业能否跨越"概念"到"业绩"鸿沟。</p>
|
||
</div>
|
||
<div class="bg-green-50 rounded-lg p-4">
|
||
<h3 class="font-semibold text-green-800 mb-2">核心驱动力</h3>
|
||
<p class="text-gray-700">监管破冰（中美双获批）+ 技术突破（MSC工艺标准化）+ 支付端探索（商保+医保丙类目录）。</p>
|
||
</div>
|
||
<div class="bg-purple-50 rounded-lg p-4">
|
||
<h3 class="font-semibold text-purple-800 mb-2">未来潜力</h3>
|
||
<p class="text-gray-700">GVHD等罕见病仅打开10亿级市场，而脑卒中（百亿级）、肝硬化（千亿级）等适应症才是估值爆发关键。</p>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
<!-- 时间轴 -->
|
||
<div class="glass-effect p-6 mb-8">
|
||
<h2 class="text-2xl font-bold text-gray-800 mb-6 flex items-center">
|
||
<i class="fas fa-clock text-blue-500 mr-3"></i>
|
||
概念事件时间轴
|
||
</h2>
|
||
<div class="relative pl-8">
|
||
<div class="timeline-line"></div>
|
||
|
||
<div class="mb-8 relative">
|
||
<div class="timeline-dot"></div>
|
||
<div class="bg-white rounded-lg p-4 shadow-sm">
|
||
<h3 class="font-bold text-lg text-gray-800">2024年9月</h3>
|
||
<p class="text-gray-600">商务部等三部委宣布在北京、上海、广东自贸区和海南自贸港允许外资进入干细胞技术开发，政策破冰。</p>
|
||
</div>
|
||
</div>
|
||
|
||
<div class="mb-8 relative">
|
||
<div class="timeline-dot"></div>
|
||
<div class="bg-white rounded-lg p-4 shadow-sm">
|
||
<h3 class="font-bold text-lg text-gray-800">2025年1月</h3>
|
||
<p class="text-gray-600">中国首款干细胞药物艾米迈托赛注射液（GVHD适应症）获批上市，定价36-50万元/疗程，标志商业化元年。</p>
|
||
</div>
|
||
</div>
|
||
|
||
<div class="mb-8 relative">
|
||
<div class="timeline-dot"></div>
|
||
<div class="bg-white rounded-lg p-4 shadow-sm">
|
||
<h3 class="font-bold text-lg text-gray-800">2025年6月</h3>
|
||
<p class="text-gray-600">九芝堂、中源协和等企业密集披露临床进展（脑卒中、牙周炎、肺泡蛋白沉积症），海南博鳌乐城启动首批干细胞临床项目收费试点。</p>
|
||
</div>
|
||
</div>
|
||
|
||
<div class="relative">
|
||
<div class="timeline-dot"></div>
|
||
<div class="bg-white rounded-lg p-4 shadow-sm">
|
||
<h3 class="font-bold text-lg text-gray-800">2025年7月</h3>
|
||
<p class="text-gray-600">九芝堂路演明确骨髓MSC扩增技术全球领先（单脐带产能1500万份），脑卒中适应症预计2029年完成III期。</p>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
<!-- 核心逻辑与市场分析 -->
|
||
<div class="glass-effect p-6 mb-8">
|
||
<h2 class="text-2xl font-bold text-gray-800 mb-6 flex items-center">
|
||
<i class="fas fa-chart-line text-green-500 mr-3"></i>
|
||
核心逻辑与市场分析
|
||
</h2>
|
||
|
||
<div class="grid grid-cols-1 md:grid-cols-2 gap-6 mb-6">
|
||
<div>
|
||
<h3 class="font-bold text-lg text-gray-800 mb-3">核心驱动力</h3>
|
||
<div class="space-y-3">
|
||
<div class="highlight-box">
|
||
<h4 class="font-semibold text-gray-700">技术端</h4>
|
||
<p class="text-gray-600">间充质干细胞（MSC）占国内临床管线80%以上，九芝堂低氧扩增技术将单脐带产能提升至1500万份（行业平均3000-1万份），成本有望降至5万元/疗程（当前8-10万）。</p>
|
||
</div>
|
||
<div class="highlight-box">
|
||
<h4 class="font-semibold text-gray-700">政策端</h4>
|
||
<p class="text-gray-600">CDE 2024年发布5项干细胞临床指南，海南博鳌允许未上市产品收费试用（2-15万元/次），加速真实世界数据积累。</p>
|
||
</div>
|
||
<div class="highlight-box">
|
||
<h4 class="font-semibold text-gray-700">需求端</h4>
|
||
<p class="text-gray-600">中国1.3亿糖尿病患者（Vertex胰岛干细胞治愈11/12例）、1000万脑卒中后遗症患者（九芝堂II期数据预计2025H2读出），存在巨大未满足需求。</p>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
<div>
|
||
<h3 class="font-bold text-lg text-gray-800 mb-3">市场热度与预期差</h3>
|
||
<div class="bg-yellow-50 rounded-lg p-4 mb-4">
|
||
<h4 class="font-semibold text-yellow-800 mb-2">市场热度</h4>
|
||
<p class="text-gray-700">2025年1月首药获批后，干细胞概念股单日涨幅超10%（中源协和、九芝堂涨停），但随后回调（2024年5月热度曾暴跌62.55%）。</p>
|
||
</div>
|
||
<div class="bg-red-50 rounded-lg p-4 mb-4">
|
||
<h4 class="font-semibold text-red-800 mb-2">被高估的叙事</h4>
|
||
<p class="text-gray-700">市场过度关注GVHD等罕见病（市场规模<10亿），忽视脑卒中、肝硬化等大病种临床风险（需2000例以上III期）。</p>
|
||
</div>
|
||
<div class="bg-green-50 rounded-lg p-4">
|
||
<h4 class="font-semibold text-green-800 mb-2">被低估的细节</h4>
|
||
<p class="text-gray-700">九芝堂肺泡蛋白沉积症（PAP）II期数据即将公布（钟南山团队），该适应症全球无竞品，可能成为首个10亿级单品。</p>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
<!-- 关键催化剂与未来路径 -->
|
||
<div class="glass-effect p-6 mb-8">
|
||
<h2 class="text-2xl font-bold text-gray-800 mb-6 flex items-center">
|
||
<i class="fas fa-rocket text-purple-500 mr-3"></i>
|
||
关键催化剂与未来路径
|
||
</h2>
|
||
|
||
<div class="grid grid-cols-1 md:grid-cols-2 gap-6">
|
||
<div>
|
||
<h3 class="font-bold text-lg text-gray-800 mb-4">近期催化剂（3-6个月）</h3>
|
||
<div class="space-y-4">
|
||
<div class="flex items-start">
|
||
<div class="bg-purple-100 rounded-full p-2 mr-3 mt-1">
|
||
<i class="fas fa-flask text-purple-600"></i>
|
||
</div>
|
||
<div>
|
||
<h4 class="font-semibold text-gray-700">九芝堂PAP适应症II期数据</h4>
|
||
<p class="text-gray-600 text-sm">2025年8月：若血氧浓度改善>20%，将启动III期并锁定全球独家。</p>
|
||
</div>
|
||
</div>
|
||
|
||
<div class="flex items-start">
|
||
<div class="bg-blue-100 rounded-full p-2 mr-3 mt-1">
|
||
<i class="fas fa-tooth text-blue-600"></i>
|
||
</div>
|
||
<div>
|
||
<h4 class="font-semibold text-gray-700">中源协和牙周炎II期数据</h4>
|
||
<p class="text-gray-600 text-sm">2025年底：牙槽骨再生>3mm即可申报III期，50亿峰值市场预期落地。</p>
|
||
</div>
|
||
</div>
|
||
|
||
<div class="flex items-start">
|
||
<div class="bg-green-100 rounded-full p-2 mr-3 mt-1">
|
||
<i class="fas fa-map-marker-alt text-green-600"></i>
|
||
</div>
|
||
<div>
|
||
<h4 class="font-semibold text-gray-700">海南博鳌收费试点扩容</h4>
|
||
<p class="text-gray-600 text-sm">预计2025Q3新增肝硬化、糖尿病足溃疡适应症试点。</p>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
<div>
|
||
<h3 class="font-bold text-lg text-gray-800 mb-4">长期路径（2026-2030）</h3>
|
||
<div class="space-y-4">
|
||
<div class="flex items-start">
|
||
<div class="bg-indigo-100 rounded-full p-2 mr-3 mt-1">
|
||
<span class="text-indigo-600 font-bold">26</span>
|
||
</div>
|
||
<div>
|
||
<h4 class="font-semibold text-gray-700">2026年</h4>
|
||
<p class="text-gray-600 text-sm">脑卒中、肝硬化III期完成，百亿级市场打开。</p>
|
||
</div>
|
||
</div>
|
||
|
||
<div class="flex items-start">
|
||
<div class="bg-indigo-100 rounded-full p-2 mr-3 mt-1">
|
||
<span class="text-indigo-600 font-bold">27</span>
|
||
</div>
|
||
<div>
|
||
<h4 class="font-semibold text-gray-700">2027年</h4>
|
||
<p class="text-gray-600 text-sm">通用型iPSC胰岛细胞（Vertex）提交BLA，糖尿病治愈概念催化。</p>
|
||
</div>
|
||
</div>
|
||
|
||
<div class="flex items-start">
|
||
<div class="bg-indigo-100 rounded-full p-2 mr-3 mt-1">
|
||
<span class="text-indigo-600 font-bold">28+</span>
|
||
</div>
|
||
<div>
|
||
<h4 class="font-semibold text-gray-700">2028年后</h4>
|
||
<p class="text-gray-600 text-sm">干细胞+AI个性化疗法（如我武生物仿生培养设备）成为新增长点。</p>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
<!-- 产业链与核心公司 -->
|
||
<div class="glass-effect p-6 mb-8">
|
||
<h2 class="text-2xl font-bold text-gray-800 mb-6 flex items-center">
|
||
<i class="fas fa-sitemap text-indigo-500 mr-3"></i>
|
||
产业链与核心公司深度剖析
|
||
</h2>
|
||
|
||
<div class="mb-6">
|
||
<h3 class="font-bold text-lg text-gray-800 mb-3">产业链图谱</h3>
|
||
<div class="grid grid-cols-1 md:grid-cols-3 gap-4">
|
||
<div class="bg-blue-50 rounded-lg p-4 text-center">
|
||
<i class="fas fa-cogs text-blue-500 text-2xl mb-2"></i>
|
||
<h4 class="font-semibold text-blue-800">上游</h4>
|
||
<p class="text-gray-600 text-sm">细胞制备（泰林生物设备+中源协和3D培养基）</p>
|
||
</div>
|
||
<div class="bg-green-50 rounded-lg p-4 text-center">
|
||
<i class="fas fa-database text-green-500 text-2xl mb-2"></i>
|
||
<h4 class="font-semibold text-green-800">中游</h4>
|
||
<p class="text-gray-600 text-sm">存储（南京新百脐带血库+南华生物区域牌照）</p>
|
||
</div>
|
||
<div class="bg-purple-50 rounded-lg p-4 text-center">
|
||
<i class="fas fa-hospital text-purple-500 text-2xl mb-2"></i>
|
||
<h4 class="font-semibold text-purple-800">下游</h4>
|
||
<p class="text-gray-600 text-sm">应用（九芝堂脑卒中、中源协和牙周炎、我武生物伤口愈合）</p>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
<div>
|
||
<h3 class="font-bold text-lg text-gray-800 mb-3">核心玩家对比</h3>
|
||
<div class="overflow-x-auto">
|
||
<table class="min-w-full bg-white rounded-lg overflow-hidden">
|
||
<thead class="bg-gray-100">
|
||
<tr>
|
||
<th class="py-3 px-4 text-left text-gray-700 font-semibold">公司</th>
|
||
<th class="py-3 px-4 text-left text-gray-700 font-semibold">适应症布局</th>
|
||
<th class="py-3 px-4 text-left text-gray-700 font-semibold">技术壁垒</th>
|
||
<th class="py-3 px-4 text-left text-gray-700 font-semibold">风险点</th>
|
||
</tr>
|
||
</thead>
|
||
<tbody>
|
||
<tr class="border-b">
|
||
<td class="py-3 px-4 font-semibold text-gray-800">九芝堂</td>
|
||
<td class="py-3 px-4 text-gray-600">脑卒中（唯一）、PAP</td>
|
||
<td class="py-3 px-4 text-gray-600">骨髓MSC扩增1500万份/脐带</td>
|
||
<td class="py-3 px-4 text-gray-600">脑卒中III期需2000例，周期长</td>
|
||
</tr>
|
||
<tr class="border-b">
|
||
<td class="py-3 px-4 font-semibold text-gray-800">中源协和</td>
|
||
<td class="py-3 px-4 text-gray-600">牙周炎（进度最快）</td>
|
||
<td class="py-3 px-4 text-gray-600">牙髓干细胞II期数据领先</td>
|
||
<td class="py-3 px-4 text-gray-600">新生儿下滑拖累存储业务</td>
|
||
</tr>
|
||
<tr>
|
||
<td class="py-3 px-4 font-semibold text-gray-800">我武生物</td>
|
||
<td class="py-3 px-4 text-gray-600">伤口愈合（设备+细胞）</td>
|
||
<td class="py-3 px-4 text-gray-600">仿生培养设备（模拟心跳/血压）</td>
|
||
<td class="py-3 px-4 text-gray-600">干细胞业务占比低（<5%）</td>
|
||
</tr>
|
||
</tbody>
|
||
</table>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
<!-- 风险与挑战 -->
|
||
<div class="glass-effect p-6 mb-8">
|
||
<h2 class="text-2xl font-bold text-gray-800 mb-6 flex items-center">
|
||
<i class="fas fa-exclamation-triangle text-red-500 mr-3"></i>
|
||
潜在风险与挑战
|
||
</h2>
|
||
|
||
<div class="grid grid-cols-1 md:grid-cols-2 gap-4">
|
||
<div class="bg-red-50 rounded-lg p-4">
|
||
<h3 class="font-semibold text-red-800 mb-2 flex items-center">
|
||
<i class="fas fa-microscope mr-2"></i>
|
||
技术风险
|
||
</h3>
|
||
<p class="text-gray-700">iPSC胰岛细胞存在畸胎瘤风险（长征医院案例），需长期随访。</p>
|
||
</div>
|
||
|
||
<div class="bg-orange-50 rounded-lg p-4">
|
||
<h3 class="font-semibold text-orange-800 mb-2 flex items-center">
|
||
<i class="fas fa-snowflake mr-2"></i>
|
||
商业化风险
|
||
</h3>
|
||
<p class="text-gray-700">干细胞冷链运输成本占售价30%（-196℃液氮），下沉市场渗透受限。</p>
|
||
</div>
|
||
|
||
<div class="bg-yellow-50 rounded-lg p-4">
|
||
<h3 class="font-semibold text-yellow-800 mb-2 flex items-center">
|
||
<i class="fas fa-file-contract mr-2"></i>
|
||
政策风险
|
||
</h3>
|
||
<p class="text-gray-700">CDE可能收紧医疗技术备案制（2024年已要求补充数据），灰色疗法空间压缩。</p>
|
||
</div>
|
||
|
||
<div class="bg-purple-50 rounded-lg p-4">
|
||
<h3 class="font-semibold text-purple-800 mb-2 flex items-center">
|
||
<i class="fas fa-balance-scale mr-2"></i>
|
||
信息矛盾
|
||
</h3>
|
||
<p class="text-gray-700">民生证券预测牙周炎50亿市场（4%渗透率），但第四军医大学试验显示安慰剂组骨增量仅0.5mm，疗效可能被夸大。</p>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
<!-- 投资启示 -->
|
||
<div class="glass-effect p-6 mb-8">
|
||
<h2 class="text-2xl font-bold text-gray-800 mb-6 flex items-center">
|
||
<i class="fas fa-chart-pie text-teal-500 mr-3"></i>
|
||
综合结论与投资启示
|
||
</h2>
|
||
|
||
<div class="bg-gradient-to-r from-teal-50 to-blue-50 rounded-lg p-6 mb-6">
|
||
<h3 class="font-bold text-xl text-gray-800 mb-4">阶段判断</h3>
|
||
<p class="text-gray-700 text-lg">主题炒作末期 → 业绩验证初期，2025H2数据将分化龙头与概念股。</p>
|
||
</div>
|
||
|
||
<div class="grid grid-cols-1 md:grid-cols-2 gap-6 mb-6">
|
||
<div>
|
||
<h3 class="font-bold text-lg text-gray-800 mb-3">投资方向</h3>
|
||
<div class="space-y-3">
|
||
<div class="bg-green-100 rounded-lg p-4">
|
||
<h4 class="font-semibold text-green-800 flex items-center">
|
||
<i class="fas fa-star mr-2"></i>
|
||
首选九芝堂
|
||
</h4>
|
||
<p class="text-gray-700">PAP全球独家+脑卒中大适应症，催化剂密集（2025年8月数据）。</p>
|
||
</div>
|
||
<div class="bg-blue-100 rounded-lg p-4">
|
||
<h4 class="font-semibold text-blue-800 flex items-center">
|
||
<i class="fas fa-medal mr-2"></i>
|
||
次选中源协和
|
||
</h4>
|
||
<p class="text-gray-700">牙周炎进度最快+存储业务现金流支撑。</p>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
<div>
|
||
<h3 class="font-bold text-lg text-gray-800 mb-3">关键跟踪指标</h3>
|
||
<div class="space-y-3">
|
||
<div class="flex items-start">
|
||
<div class="bg-purple-100 rounded-full p-2 mr-3 mt-1">
|
||
<i class="fas fa-chart-line text-purple-600"></i>
|
||
</div>
|
||
<div>
|
||
<h4 class="font-semibold text-gray-700">九芝堂PAP II期数据</h4>
|
||
<p class="text-gray-600 text-sm">血氧改善阈值≥15%</p>
|
||
</div>
|
||
</div>
|
||
<div class="flex items-start">
|
||
<div class="bg-purple-100 rounded-full p-2 mr-3 mt-1">
|
||
<i class="fas fa-users text-purple-600"></i>
|
||
</div>
|
||
<div>
|
||
<h4 class="font-semibold text-gray-700">海南博鳌试点收费人次</h4>
|
||
<p class="text-gray-600 text-sm">2025Q3需>100例/月验证需求</p>
|
||
</div>
|
||
</div>
|
||
<div class="flex items-start">
|
||
<div class="bg-purple-100 rounded-full p-2 mr-3 mt-1">
|
||
<i class="fas fa-user-clock text-purple-600"></i>
|
||
</div>
|
||
<div>
|
||
<h4 class="font-semibold text-gray-700">中源协和牙周炎II期入组速度</h4>
|
||
<p class="text-gray-600 text-sm">200例/年能否完成</p>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
<div class="bg-red-50 rounded-lg p-4 border-l-4 border-red-500">
|
||
<h3 class="font-semibold text-red-800 mb-2">风险提示</h3>
|
||
<p class="text-gray-700">若脑卒中III期因患者招募困难延期，行业估值或回调30%以上。</p>
|
||
</div>
|
||
</div>
|
||
|
||
<!-- 关联股票数据表格 -->
|
||
<div class="glass-effect p-6">
|
||
<h2 class="text-2xl font-bold text-gray-800 mb-6 flex items-center">
|
||
<i class="fas fa-table text-indigo-500 mr-3"></i>
|
||
干细胞概念股关联数据
|
||
</h2>
|
||
|
||
<div class="table-container">
|
||
<table class="min-w-full bg-white rounded-lg overflow-hidden">
|
||
<thead class="bg-gray-100">
|
||
<tr>
|
||
<th class="py-3 px-4 text-left text-gray-700 font-semibold">股票名称</th>
|
||
<th class="py-3 px-4 text-left text-gray-700 font-semibold">行业</th>
|
||
<th class="py-3 px-4 text-left text-gray-700 font-semibold">分类</th>
|
||
<th class="py-3 px-4 text-left text-gray-700 font-semibold">产业链</th>
|
||
<th class="py-3 px-4 text-left text-gray-700 font-semibold">关联原因</th>
|
||
</tr>
|
||
</thead>
|
||
<tbody>
|
||
<tr class="border-b hover:bg-gray-50">
|
||
<td class="py-3 px-4 font-medium text-gray-800">中源协和</td>
|
||
<td class="py-3 px-4 text-gray-600">细胞制备</td>
|
||
<td class="py-3 px-4 text-gray-600">干细胞</td>
|
||
<td class="py-3 px-4 text-gray-600">上游设备/技术</td>
|
||
<td class="py-3 px-4 text-gray-600">属于细胞制备环节，涉及干细胞技术研发与产业化</td>
|
||
</tr>
|
||
<tr class="border-b hover:bg-gray-50">
|
||
<td class="py-3 px-4 font-medium text-gray-800">开能健康</td>
|
||
<td class="py-3 px-4 text-gray-600">细胞制备</td>
|
||
<td class="py-3 px-4 text-gray-600">干细胞</td>
|
||
<td class="py-3 px-4 text-gray-600">上游设备/技术</td>
|
||
<td class="py-3 px-4 text-gray-600">参与干细胞制备相关设备或技术支持</td>
|
||
</tr>
|
||
<tr class="border-b hover:bg-gray-50">
|
||
<td class="py-3 px-4 font-medium text-gray-800">四环生物</td>
|
||
<td class="py-3 px-4 text-gray-600">细胞制备</td>
|
||
<td class="py-3 px-4 text-gray-600">干细胞</td>
|
||
<td class="py-3 px-4 text-gray-600">上游设备/技术</td>
|
||
<td class="py-3 px-4 text-gray-600">在干细胞制备领域有技术布局</td>
|
||
</tr>
|
||
<tr class="border-b hover:bg-gray-50">
|
||
<td class="py-3 px-4 font-medium text-gray-800">冠昊生物</td>
|
||
<td class="py-3 px-4 text-gray-600">细胞制备</td>
|
||
<td class="py-3 px-4 text-gray-600">干细胞</td>
|
||
<td class="py-3 px-4 text-gray-600">上游设备/技术</td>
|
||
<td class="py-3 px-4 text-gray-600">主营生物材料及细胞制备技术</td>
|
||
</tr>
|
||
<tr class="border-b hover:bg-gray-50">
|
||
<td class="py-3 px-4 font-medium text-gray-800">汉商集团</td>
|
||
<td class="py-3 px-4 text-gray-600">细胞制备</td>
|
||
<td class="py-3 px-4 text-gray-600">干细胞</td>
|
||
<td class="py-3 px-4 text-gray-600">上游设备/技术</td>
|
||
<td class="py-3 px-4 text-gray-600">通过收购或投资布局干细胞制备领域</td>
|
||
</tr>
|
||
<tr class="border-b hover:bg-gray-50">
|
||
<td class="py-3 px-4 font-medium text-gray-800">正海生物</td>
|
||
<td class="py-3 px-4 text-gray-600">细胞制备</td>
|
||
<td class="py-3 px-4 text-gray-600">干细胞</td>
|
||
<td class="py-3 px-4 text-gray-600">上游设备/技术</td>
|
||
<td class="py-3 px-4 text-gray-600">专注生物再生材料及细胞制备技术</td>
|
||
</tr>
|
||
<tr class="border-b hover:bg-gray-50">
|
||
<td class="py-3 px-4 font-medium text-gray-800">香雪制药</td>
|
||
<td class="py-3 px-4 text-gray-600">细胞制备</td>
|
||
<td class="py-3 px-4 text-gray-600">干细胞</td>
|
||
<td class="py-3 px-4 text-gray-600">上游设备/技术</td>
|
||
<td class="py-3 px-4 text-gray-600">涉及干细胞制备相关药物研发</td>
|
||
</tr>
|
||
<tr class="border-b hover:bg-gray-50">
|
||
<td class="py-3 px-4 font-medium text-gray-800">泰林生物</td>
|
||
<td class="py-3 px-4 text-gray-600">细胞制备</td>
|
||
<td class="py-3 px-4 text-gray-600">干细胞</td>
|
||
<td class="py-3 px-4 text-gray-600">上游设备/技术</td>
|
||
<td class="py-3 px-4 text-gray-600">提供细胞制备所需的生物培养设备</td>
|
||
</tr>
|
||
<tr class="border-b hover:bg-gray-50">
|
||
<td class="py-3 px-4 font-medium text-gray-800">南京新百</td>
|
||
<td class="py-3 px-4 text-gray-600">细胞存储</td>
|
||
<td class="py-3 px-4 text-gray-600">干细胞</td>
|
||
<td class="py-3 px-4 text-gray-600">中游存储</td>
|
||
<td class="py-3 px-4 text-gray-600">拥有脐带血干细胞存储核心业务</td>
|
||
</tr>
|
||
<tr class="border-b hover:bg-gray-50">
|
||
<td class="py-3 px-4 font-medium text-gray-800">南华生物</td>
|
||
<td class="py-3 px-4 text-gray-600">细胞存储</td>
|
||
<td class="py-3 px-4 text-gray-600">干细胞</td>
|
||
<td class="py-3 px-4 text-gray-600">中游存储</td>
|
||
<td class="py-3 px-4 text-gray-600">主营干细胞存储及再生医学服务</td>
|
||
</tr>
|
||
<tr class="border-b hover:bg-gray-50">
|
||
<td class="py-3 px-4 font-medium text-gray-800">戴维医疗</td>
|
||
<td class="py-3 px-4 text-gray-600">细胞存储</td>
|
||
<td class="py-3 px-4 text-gray-600">干细胞</td>
|
||
<td class="py-3 px-4 text-gray-600">中游存储</td>
|
||
<td class="py-3 px-4 text-gray-600">提供细胞存储设备及技术支持</td>
|
||
</tr>
|
||
<tr class="border-b hover:bg-gray-50">
|
||
<td class="py-3 px-4 font-medium text-gray-800">冠昊生物</td>
|
||
<td class="py-3 px-4 text-gray-600">细胞应用</td>
|
||
<td class="py-3 px-4 text-gray-600">脑损伤治疗</td>
|
||
<td class="py-3 px-4 text-gray-600">下游应用</td>
|
||
<td class="py-3 px-4 text-gray-600">干细胞在脑损伤修复领域的临床研究</td>
|
||
</tr>
|
||
<tr class="border-b hover:bg-gray-50">
|
||
<td class="py-3 px-4 font-medium text-gray-800">正海生物</td>
|
||
<td class="py-3 px-4 text-gray-600">细胞应用</td>
|
||
<td class="py-3 px-4 text-gray-600">脑损伤治疗</td>
|
||
<td class="py-3 px-4 text-gray-600">下游应用</td>
|
||
<td class="py-3 px-4 text-gray-600">生物材料与干细胞结合用于神经修复</td>
|
||
</tr>
|
||
<tr class="border-b hover:bg-gray-50">
|
||
<td class="py-3 px-4 font-medium text-gray-800">迈普医学</td>
|
||
<td class="py-3 px-4 text-gray-600">细胞应用</td>
|
||
<td class="py-3 px-4 text-gray-600">脑损伤治疗</td>
|
||
<td class="py-3 px-4 text-gray-600">下游应用</td>
|
||
<td class="py-3 px-4 text-gray-600">神经再生材料及细胞治疗研发</td>
|
||
</tr>
|
||
<tr class="border-b hover:bg-gray-50">
|
||
<td class="py-3 px-4 font-medium text-gray-800">佰仁医疗</td>
|
||
<td class="py-3 px-4 text-gray-600">细胞应用</td>
|
||
<td class="py-3 px-4 text-gray-600">脑损伤治疗</td>
|
||
<td class="py-3 px-4 text-gray-600">下游应用</td>
|
||
<td class="py-3 px-4 text-gray-600">生物材料在脑损伤修复中的应用</td>
|
||
</tr>
|
||
<tr class="border-b hover:bg-gray-50">
|
||
<td class="py-3 px-4 font-medium text-gray-800">何氏眼科</td>
|
||
<td class="py-3 px-4 text-gray-600">细胞应用</td>
|
||
<td class="py-3 px-4 text-gray-600">眼科治疗</td>
|
||
<td class="py-3 px-4 text-gray-600">下游应用</td>
|
||
<td class="py-3 px-4 text-gray-600">干细胞技术在眼科疾病中的临床探索</td>
|
||
</tr>
|
||
<tr class="border-b hover:bg-gray-50">
|
||
<td class="py-3 px-4 font-medium text-gray-800">济民健康</td>
|
||
<td class="py-3 px-4 text-gray-600">细胞应用</td>
|
||
<td class="py-3 px-4 text-gray-600">糖尿病治疗</td>
|
||
<td class="py-3 px-4 text-gray-600">下游应用</td>
|
||
<td class="py-3 px-4 text-gray-600">干细胞在糖尿病并发症治疗中的应用</td>
|
||
</tr>
|
||
<tr class="border-b hover:bg-gray-50">
|
||
<td class="py-3 px-4 font-medium text-gray-800">赤天化</td>
|
||
<td class="py-3 px-4 text-gray-600">细胞应用</td>
|
||
<td class="py-3 px-4 text-gray-600">糖尿病治疗</td>
|
||
<td class="py-3 px-4 text-gray-600">下游应用</td>
|
||
<td class="py-3 px-4 text-gray-600">通过子公司布局干细胞治疗糖尿病领域</td>
|
||
</tr>
|
||
<tr class="hover:bg-gray-50">
|
||
<td class="py-3 px-4 font-medium text-gray-800">我武生物</td>
|
||
<td class="py-3 px-4 text-gray-600">细胞应用</td>
|
||
<td class="py-3 px-4 text-gray-600">糖尿病治疗</td>
|
||
<td class="py-3 px-4 text-gray-600">下游应用</td>
|
||
<td class="py-3 px-4 text-gray-600">干细胞在代谢疾病治疗中的研发</td>
|
||
</tr>
|
||
</tbody>
|
||
</table>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
<script src="https://cdn.jsdelivr.net/npm/tsparticles@3/tsparticles.bundle.min.js"></script>
|
||
<script>
|
||
// 粒子背景效果
|
||
tsParticles.load("particles-js", {
|
||
particles: {
|
||
number: {
|
||
value: 30,
|
||
density: {
|
||
enable: true,
|
||
value_area: 800
|
||
}
|
||
},
|
||
color: {
|
||
value: "#4f46e5"
|
||
},
|
||
shape: {
|
||
type: "circle"
|
||
},
|
||
opacity: {
|
||
value: 0.5,
|
||
random: true
|
||
},
|
||
size: {
|
||
value: 3,
|
||
random: true
|
||
},
|
||
move: {
|
||
enable: true,
|
||
speed: 2,
|
||
direction: "none",
|
||
random: true,
|
||
straight: false,
|
||
out_mode: "out"
|
||
}
|
||
},
|
||
interactivity: {
|
||
detect_on: "canvas",
|
||
events: {
|
||
onhover: {
|
||
enable: true,
|
||
mode: "repulse"
|
||
}
|
||
}
|
||
},
|
||
retina_detect: true
|
||
});
|
||
</script>
|
||
</body>
|
||
</html>
|
||
``` |